# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-186940
Filing Date
2026-04-28
Accepted
2026-04-28 16:06:10
Documents
11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | bolt-20260427.htm iXBRL | DEFA14A | 26762
2 | GRAPHIC | img119940086_0.jpg | GRAPHIC | 329667
3 | GRAPHIC | img119940086_1.jpg | GRAPHIC | 147240
| Complete submission text file | 0001193125-26-186940.txt |  | 1342432

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | bolt-20260427.xsd | EX-101.SCH | 7383
14 | EXTRACTED XBRL INSTANCE DOCUMENT | bolt-20260427_htm.xml | XML | 1303

Mailing Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Business Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 650-665-9295
Bolt Biotherapeutics, Inc. (Filer) CIK: 0001641281 (see all company filings)

EIN.: 472804636 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39988 | Film No.: 26907621
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)